MMS is collaborating with the DIA for an upcoming complimentary webinar, “Optimizing the Use of Clinical Trial Disclosure Systems to Meet Complex and Evolving Global Regulatory Requirements.” Learning Objectives Determine key drivers for the use of technology to...

Pfizer has selected MMS Holdings Inc. (MMS), headquartered in Canton, MI, as a preferred provider for support writing plain language summaries of the results for all its Phase 2 and 3 clinical trials. In advance of implementation of EU Clinical Trial Regulation No....

Emmaus Life Sciences Inc. (Emmaus) has announced that EndariTM for the treatment of sickle cell disease (SCD) has been recommended for approval by the Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee. In a10–3 vote, the committee recognized that...

Canton, Mich. (March 14, 2016) — MMS Holdings Inc., a specialty data-focused CRO, has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial...

HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India. The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality...

Canton, Mich. (June 11, 2014) – MMS Holdings Inc., a clinical research organization that focuses on regulatory submission support for the pharmaceutical and biotech industries, and the Wayne State University (WSU) Graduate School announced today the creation of a...

Canton, Mich. (August 1, 2013) – MMS Holdings Inc. today announced that it has been selected to partner with Knopp Biosciences to provide best-in-class pharmacovigilance services in support of their compound, dexpramipexole. The MMS Holdings team offers an efficient,...